Asset
Icovamenib
Biomea Fusion Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06152042 | phase2 | completed | 2023-12-28 | 2025-05-20 | Biomea Fusion Inc. | Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus |
| NCT05731544 | phase1_2 | completed | 2022-08-17 | 2024-11-18 | Biomea Fusion Inc. | Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D) |
| NCT05153330 | phase1 | terminated | 2022-01-24 | 2025-02-13 | Biomea Fusion Inc. | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL |
| NCT05631574 | phase1 | terminated | 2023-01-12 | 2025-01-15 | Biomea Fusion Inc. | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer |
FDA applications (0)
This company has no applications containing this asset.